[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"The sympathy play: $CLPT (ClearPoint Neuro) provides the brain delivery tech that $QUREs gene therapy requires. They move together. Watch $CLPT as your canaryif it fails $QURE could follow"
X Link @_samputnam 2025-10-16T16:57Z XXX followers, XXX engagements
"$CLPT fanatics have been screaming about this for years now. The lowest risk gene cell therapy programs you can make are for the CNS"
X Link @AB1001_disciple 2025-10-13T16:45Z XXX followers, 3559 engagements
"It looks like AAV gene therapy is finding its niche: local delivery of relatively low doses (E10-E12 total vg) in tissues as contained as possible. Recent clinical wins by $QURE's AMT-130 (intra-parenchymal Huntington's) and $REGN's DB-OTO (intracochlear inherited deafness) support this trend. These follow prior approved drugs like $RHHBY's Luxturna (subretinal LCA2) and $PTCT's Upstaza (intra-parenchymal AADC deficiency) also delivered locally. $NVS' Zolgensma is a special case -- although delivered systemically at relatively high doses the infant BBB remains permissive allowing efficient"
X Link @GerardCaelles 2025-10-13T16:19Z 1099 followers, 13.8K engagements
"@ReplyGuy_Cap They are big in Alzheimers and HD and $qures pipeline could be a perfect fit"
X Link @canoebrookbl 2025-10-12T15:09Z XXX followers, XXX engagements